Prosecution Insights
Last updated: November 12, 2026
Application No. 18/249,383

MULTI-LAYERED COLLAGEN STRUCTURE

Final Rejection §103
Filed
Apr 18, 2023
Priority
Nov 05, 2020 — provisional 63/109,888 +1 more
Examiner
COUGHLIN, DANIEL F
Art Unit
1619
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Datum Dental Ltd.
OA Round
2 (Final)
39%
Grant Probability
At Risk
3-4
OA Rounds
57%
With Interview

Examiner Intelligence

Grants only 39% of cases
39%
Career Allowance Rate
205 granted / 527 resolved
-21.1% vs TC avg
Strong +18% interview lift
Without
With
+17.8%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
36 currently pending
Career history
569
Total Applications
across all art units

Office Action

§103
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined pursuant to the first inventor to file provisions of the AIA . DETAILED ACTION Status of the Claims The Examiner acknowledges receipt of Applicants’ Response, filed 7 July 2026. No claims are amended therein. Claims 5, 7, and 8 remain withdrawn as being directed to a non-elected invention. Consequently, claims 1 - 4 and 6 are available for active consideration. Information Disclosure Statement The Examiner has considered the information disclosure statement (IDS) filed 7 July 2026, which is now of record in the file. REJECTIONS MAINTAINED Rejections Pursuant to 35 U.S.C. § 103 The following is a quotation of 35 U.S.C. § 103 that forms the basis for all obviousness rejections set forth in this Office Action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102 of this title, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries set forth in Graham v. John Deere Co., 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the Examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention absent any evidence to the contrary. Applicants are advised of the obligation pursuant to 37 CFR § 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the Examiner to consider the applicability of 35 U.S.C. § 102(b)(2)(C) for any potential 35 U.S.C. § 102(a)(2) prior art against the later invention. The rejection of claims 1 – 4 and 6 pursuant to 35 U.S.C. § 103, as being obvious over US 2014/0105954 A1 to Gleeson, J., et al., published 17 April 2014, identified on the Information Disclosure Statement (IDS) filed 4 September 2023, cite no. 1 (USPATAPP) (“Gleeson ‘954”), is hereby maintained. The reference does not disclose quantitative values for the densities of layers in the multi-layer scaffolds with sufficient specificity to anticipate the claimed invention. Hence, this rejection is made pursuant to 35 U.S.C. § 103. The Invention As Claimed Applicants claim a layered structure comprising at least two collagen layers, wherein the layered structure includes a gradient of densities, wherein the at least two collagen layers comprise at least one first collagen layer and at least one second collagen layer, wherein the at least one second collagen layer (low density layer) has a density of up to about 90% of the first collagen layer (high density layer), wherein the at least two collagen layers comprise at least two first collagen layers and at least one second collagen layer, wherein the at least one second collagen layer is positioned between each of the at least two first collagen layers, and wherein the at least one second collagen layer (low density layer) has a density of up to about 90% of the at least two first collagen layers each independently. Applicants also claim a surgical scaffold comprising a layered structure comprising at least two collagen layers, wherein the layered structure includes a gradient of densities. The Teachings of the Cited Art Gleeson ‘954 discloses a multi-layer collagen scaffold (see Abstract), wherein the scaffold is prepared by a process wherein each layer is formed in a separate freezing or lyophilization step so that the freezing or lyophilization conditions of each step may be independently varied which allows the pore structure of each layer of the scaffold to be individually optimized (see ¶[0019]), wherein each layer in the multi-layer scaffold is compositionally distinct in that the layers differ in terms of their composition and/or morphology, the layers differing in terms of parameters such as hydroxyapatite (HA) content, type of collagen, amount of collagen, type of glycosaminoglycan (GAG), and quantity of GAG (see ¶[0029]), wherein, preferably, the scaffold has three layers (see ¶[0024]), wherein, in a specific embodiment (a three-layer collagen scaffold) a first layer comprises collagen and hydroxyapatite, a second layer comprises collagen and hydroxyapatite in which the collagen content is different from the first layer, and the third layer comprises collagen and little or no hydroxyapatite, and optionally a polymer and/or a biologically-active molecule (see ¶[0029]), wherein the pore size, and/or pore size distribution gradient, are varied within each layer independently by varying the slurry thickness used for each layer, and the individual layer thickness can be varied in each of the layers of the multi-layer scaffold between 1 mm and 15 mm using different volumes of slurry during the freezing or lyophilization process (see ¶[0040]), and wherein the multi-layer collagen scaffold comprises a plurality of freeze-dried layers in which a first layer comprises collagen, typically Type I collagen, and HA, a second layer comprises one or more types of collagen (typically Type I collagen and a non-Type I collagen, such as Type II collagen), HA and optionally one or more types of GAG, and a third layer comprises one or more types of collagen (typically two types of collagen, i.e. Type I and a non-Type I collagen, such as Type II collagen, and optionally one or more types of GAG and a biologic (see ¶[0068]). Application of the Cited Art to the Claims It would have been prima facie obvious before the filing date of the claimed invention to prepare a two- or three-layer collagen scaffold with a first layer comprising collagen and hydroxyapatite, a second layer comprising collagen and hydroxyapatite in which the collagen content is different from the first layer, and a third layer comprising collagen and little or no hydroxyapatite, and optionally a polymer and/or a biologically-active molecule, wherein the pore size, and/or pore size distribution gradient, are varied within each layer independently by varying the slurry thickness used for each layer, wherein the multi-layer collagen scaffold comprises a plurality of freeze-dried layers in which a first layer comprises collagen, typically Type I collagen, and HA, a second layer comprises one or more types of collagen (typically Type I collagen and a non-Type I collagen, such as Type II collagen), HA and optionally one or more types of GAG, and a third layer comprises one or more types of collagen (typically two types of collagen, i.e. Type I and a non-Type I collagen, such as Type II collagen, and optionally one or more types of GAG and a biologic. One of skill in the art would be motivated to do so, with a reasonable expectation of success in so doing, by the teachings of the reference to the effect that the freezing or lyophilization conditions of each step in the process of fabricating individual layers may be independently varied, allowing for the pore structure of each layer of the layered scaffold to be individually optimized, which is vitally important in osteochondral repair applications, as chondrocytes and osteoblasts require vastly different conditions for optimal in vivo behavior (see ¶[0019]). With respect to the process limitations recited claim 1, it is the Examiner’s position that such recitations effectively render the claim a product-by-process claim. These types of claims are examined on the limitations of the product. See MPEP § 2113, citing In re Thorpe, 111 F.2d 695, 698, 227 USPQ 964, 966 (Fed. Cir. 1985) “[E]ven though product-by-process claims are limited by and defined by the process, determination of patentability is based on the product itself. The patentability of a product does not depend on its method of production. If the product of the product-by-process claim is the same as or obvious from a product of the prior art, the claim is unpatentable even though the prior product was made by a different process.” Furthermore, upon establishing a prima facie case, the burden of persuasion shifts to the Applicant. See MPEP 2113, citing In re Fessmann, 489 F.2d 742, 744, 180 USPQ 324, 326 (CCPA 1974) “The Patent Office bears a lesser burden of proof in making out a case of prima facie obviousness for product-by-process claims because of their peculiar nature” than when a product is claimed in the conventional fashion. With respect to the limitations recited in claims 2 and 4 directed to relative densities between adjacent layers in the multi-layer scaffolds, the Examiner notes that the reference does not expressly teach relative densities among the layers of the disclosed scaffolds. However, given the compositional differences disclosed for each layer in an exemplified three-layer scaffold, it is the Examiner’s position that the different layers would necessarily have different densities and, thus, would read on the limitations in question. Furthermore, the reference teaches that each layer in the multi-layer scaffold is compositionally distinct in that the layers differ in terms of their composition and/or morphology, the layers differing in terms of parameters such as hydroxyapatite (HA) content, type of collagen, amount of collagen, type of glycosaminoglycan (GAG), and quantity of GAG (see ¶[0029]). Consequently, it is the Examiner’s position, based on this disclosure, that adjusting the various parameters for the preparation of, and compositional makeup of each layer to achieve specific or relative densities among the layers would amount to nothing more than optimization of result-effective variables, the exercise of which is well with the expertise of one of ordinary skill in the appropriate art. Consequently, in the absence of evidence as to the criticality of such parameter, this limitation cannot support patentability. See MPEP § 2144.05 II. A. In light of the forgoing discussion, the Examiner concludes that the subject matter defined by claims 1 – 4 and 6 would have been obvious within the meaning of 35 USC § 103. Response to Applicants’ Arguments The Examiner has considered the arguments offered by Applicants in their Response of 7 July 2026, but does not find them persuasive. Applicants first argue that Gleeson ‘954 does not teach or suggest a “gradient of densities.” The Examiner respectfully disagrees. As set forth in the rejection of record, the reference explicitly discloses that each layer in the disclosed multi-layer construct is formed in a separate freezing or lyophilization step so that the freezing or lyophilization conditions of each step may be independently varied which allows the pore structure of each layer of the scaffold to be individually optimized (see ¶[0019]). In addition, the reference discloses that each layer in the multi-layer scaffold is compositionally distinct in that the layers differ in terms of their composition and/or morphology, the layers differing in terms of parameters such as hydroxyapatite (HA) content, type of collagen, amount of collagen, type of glycosaminoglycan (GAG), and quantity of GAG (see ¶[0029]). It is the Examiner’s position that one of ordinary skill in the relevant art would recognize, first of all, that the incredible flexibility in the design and fabrication of these multi-layer constructs produces nearly endless possibilities for final compositions and structures; secondly, the skilled artisan would recognize that the multiple variables involved in the design of individual layers would necessarily result in differences in the densities of the layers, depending on specific compositional characteristics, such as type of collagen, amount and type of ceramic, amount and type of GAG’s, and even the lyophilization and drying process. Using the flexibilities of the disclosed processes, the skilled artisan can optimize each layer to tailor the constructs to prospective site of implantation of the resulting scaffolds. Applicants also argue that the rejection’s reliance on optimization is not supported by the reference’s disclosures. However, it is the Examiner’s position that, although Gleeson ‘954 does not identify or address densities of the layers as being a parameter being specifically used in the design of a multi-layer construct, the fact that Applicants have recognized another advantage which would flow naturally from following the suggestion of the prior art cannot be the basis for patentability when the differences would otherwise be obvious. See Ex parte Obiaya, 227 USPQ 58, 60 (Bd. Pat. App. & Inter. 1985). In this regard, Applicants are reminded that the invention as claimed is directed to a composition of matter, and that, as a consequence, the reasons for combining the teachings of multiple references, or otherwise modifying the teachings of a primary reference, are not necessarily controlling to the patentability of the compositions, as claimed. The reason or motivation to modify the reference may often suggest what the inventor has done, but for a different purpose or to solve a different problem. It is not necessary that the prior art suggest the combination or modification to achieve the same advantage or result discovered by applicant. See, e.g., In re Kahn, 441 F.3d 977, 987, 78 USPQ2d 1329, 1336 (Fed. Cir. 2006). Applicants also argue that the cited reference does not provide a motivation to use the compression process that is recited in claim 1. However, as explained at length in the rejection of record, the patentability of the claimed invention is decided on the basis of compositional and structural characteristics of the composition of the invention, and not on the processes used to prepare the composition, unless Applicants can demonstrate that the compositions prepared by other methods differ significantly in composition and/or structure. See MPEP § 2113: Even though product-by process claims are limited by and defined by the process, determination of patentability is based on the product itself. The patentability of a product does not depend on its method of production. If the product in the product-by-process claim is the same as or obvious from a product of the prior art, the claim is unpatentable even though the prior product was made by a different process. Consequently, based on the above discussion, Applicants’ arguments are unpersuasive, and claims 1 - 4 and 6 stand rejected as obvious pursuant to 35 U.S.C. § 103. NO CLAIM IS ALLOWED. THIS ACTION IS MADE FINAL. Applicants are reminded of the extension of time policy as set forth in 37 CFR § 1.136(a). PNG media_image1.png 18 19 media_image1.png Greyscale A shortened statutory period for reply to this Final Action is set to expire THREE MONTHS from the mailing date of this action. In the event a first Response is filed within TWO MONTHS of the mailing date of this Final Action and the Advisory Action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the Advisory Action is mailed, and any extension fee pursuant to 37 CFR § 1.136(a) will be calculated from the mailing date of the Advisory Action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this Final Action. CONCLUSION Any inquiry concerning this communication or any other communications from the Examiner should be directed to Daniel F. Coughlin whose telephone number is (571)270-3748. The Examiner can normally be reached on M - F 8:30 a.m. - 5:00 p.m. If attempts to reach the Examiner by telephone are unsuccessful, the Examiner’s supervisor, David Blanchard, can be reached on (571)272-0827. The fax phone number for the organization where this application or proceeding is assigned is (571)273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. /DANIEL F COUGHLIN/ Examiner, Art Unit 1619 /DAVID J BLANCHARD/ Supervisory Patent Examiner, Art Unit 1619
Read full office action

Prosecution Timeline

Apr 18, 2023
Application Filed
Apr 08, 2026
Non-Final Rejection mailed — §103
Jul 07, 2026
Response Filed
Sep 30, 2026
Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12788842
OSTEOTROPIC BONE REPLACEMENT
4y 11m to grant Granted Nov 10, 2026
Patent 12779087
BONE REGENERATION MATERIAL
4y 10m to grant Granted Nov 03, 2026
Patent 12741128
MICRONEEDLE PARTICLES, COMPOSITIONS, AND METHODS OF TREATMENT AND DELIVERING A SUBSTANCE OF INTEREST
2y 2m to grant Granted Sep 22, 2026
Patent 12734128
GASTRIC RESIDENCE SYSTEMS HAVING A FILAMENT FOR IMPROVED GASTRIC RESIDENCE
4y 4m to grant Granted Sep 15, 2026
Patent 12714571
POROUS COMPOSITE BIOMATERIALS AND RELATED METHODS
2y 2m to grant Granted Aug 25, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
39%
Grant Probability
57%
With Interview (+17.8%)
Moderate
PTA Risk
Based on 527 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month